首页

Zhaoke Ophthalmology's Presbyopia Drug YUVEZZI™ Met the Primary Endpoint in its Phase II Trial in China

read

2026-09-04

511

Zhaoke Ophthalmology Announces 2026 Interim Results

read

2026-08-28

863

Zhaoke Ophthalmology Limited Entering an Exclusive Distribution and Promotion Agreement with Pharmentum Biopharmato to Commercialize Epinastine Hydrochloride Eye Drops in China (Excluding Hong Kong, Macau and Taiwan)

read

2026-08-12

764

Zhaoke's Innovative Presbyopia Drug YUVEZZI™ Approved in Macau

read

2026-07-20

1099

Zhaoke Ophthalmology Acquires the Global Rights of Atropine Sulfate Eye Drops, an Innovative Drug for Myopia Progression Control

read

2026-07-13

1493

首页 1 2 3 4 5 尾页

Guangzhou Headquarters

Tel: 020-39062828

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

粤公网安备 44011502000975号

粤ICP备2022095718号

Wechat

Guangzhou Headquarters

Tel: 020-39062888

E-mail: info@zkoph.com

Add: No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangzhou

Hong Kong Headquarters

Tel: (852)23145100

E-mail: info@zkoph.com

Add: Unit 716, 7/F, Building 12W Phase 3, Hong Kong Science Park Shatin, Hong Kong

粤公网安备 44011502000975号

粤ICP备2022095718号

Wechat